非IgM型淋巴浆细胞淋巴瘤的临床及生物学特征
回顾性分析中国医学科学院血液病医院1993年7月至2020年8月收治的340例淋巴浆细胞淋巴瘤患者,其中非IgM型23例、华氏巨球蛋白血症317例。非IgM型组女性、脾大及结外侵犯比例更高,MYD88突变率55.6%,一线治疗总体缓解率87.5%,两组PFS和OS差异无统计学意义。
要点
- 非IgM型淋巴浆细胞淋巴瘤占340例LPL中的23例,其中14例分泌单克隆IgG、2例IgA、7例不分泌。
- 非IgM型组女性比例56.5%,高于WM组的27.3%(P=0.007)。
- 非IgM型组一线治疗总体缓解率87.5%,3年PFS率71.4%、OS率68.9%。
核心结论
- 非IgM型LPL与WM患者的临床及生物学特征相似,但非IgM型LPL组女性、结外受累比例更高,生存及预后与WM患者相似。
研究设计与样本
- 回顾性收集中国医学科学院血液病医院1993年7月至2020年8月收治的340例LPL患者临床资料,非IgM型LPL组23例,华氏巨球蛋白血症(WM)组317例,比较两组临床及生物学特征。
主要发现
- 23例非IgM型LPL中,2例分泌单克隆性IgA,14例分泌单克隆性IgG,7例不分泌单克隆性免疫球蛋白。
- 非IgM型LPL和WM患者中位年龄均为62(35~81)岁。
- 与WM组相比,非IgM型LPL组女性比例更高(56.5%对27.3%,P=0.007),脾大比例更高(60.1%对43.8%,P=0.100),结外侵犯比例更高(21.7%对12.3%,P=0.672)。
- 非IgM型LPL组18例进行了MYD88基因相关检测,阳性率55.6%。
- 非IgM型LPL组17例接受治疗,启动治疗比例与WM组相当(94.4%对92.7%,P=0.488);16例进行疗效评价,一线治疗总体缓解率87.5%。
关键数值与推荐
- 非IgM型LPL组女性比例56.5%对WM组27.3%(P=0.007)。
- 非IgM型LPL组脾大比例60.1%对WM组43.8%(P=0.100)。
- 非IgM型LPL组结外侵犯比例21.7%对WM组12.3%(P=0.672)。
- 非IgM型LPL组启动治疗比例94.4%对WM组92.7%(P=0.488)。
- 非IgM型LPL组一线治疗总体缓解率87.5%,3年PFS率71.4%、OS率68.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: The study aims to explore the clinical and biological characteristics of patients with non-IgM lymphoplasmacytic lymphoma (LPL) . Methods: The clinical data of 340 patients with LPL admitted to the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College were collected retrospectively, including 23 cases of the non-IgM LPL and 317 cases of the Waldenström's macroglobulinemia (WM) , from July 1993 to August 2020. The clinical and biological characteristics of the two groups were compared. Results: Among 23 patients with the non-IgM type LPL, two patients secreted monoclonal IgA, 14 patients secreted monoclonal IgG, and seven patients did not secrete monoclonal immunoglobulin. The median age of the non-IgM LPL and WM were both 62 (35-81) years old. Compared with the WM group, the proportion of women (56.5% vs 27.3%, P=0.007) , the proportion of splenomegaly (60.1% vs 43.8%, P=0.100) , and the proportion of extranodal invasion (21.7% vs 12.3%, P=0.672) in non-IgM LPL group were higher. Eighteen patients were tested for MYD88 gene mutation, and the overall mutation rate of MYD88 was 55.6%. In the non-IgM LPL group, a total of 17 patients received treatment, which had a comparable proportion (94.4% vs 92.7%, P=0.488) to the WM group. Sixteen patients were evaluated for efficacy, and the overall remission rate of the first-line treatment was 87.5%. The median follow-up time was 33.9 (3.5-125.1) months, and the median PFS and OS were both not reached. The 3-year PFS and OS rates were 71.4% and 68.9%, respectively. In the WM group, the median PFS was 66.2 months and the median OS was 78.1 months. Compared with the WM group, in the non-IgM group no significant differences in PFS (P=0.340) and OS (P=0.544) were seen. Conclusion: The clinical and biological characteristics of the non-IgM LPL and WM patients were similar. However, the proportion of women and extranodal involvement were higher in the non-IgM LPL group. The survival and prognosis of the non-IgM LPL patients were similar to those of the WM patients. 目的: 探索非IgM型淋巴浆细胞淋巴瘤(LPL)患者的临床及生物学特征。 方法: 回顾性收集中国医学科学院血液病医院1993年7月至2020年8月收治的340例LPL患者的临床资料,其中23例为非IgM型LPL组,317例为华氏巨球蛋白血症(WM)组。比较两组患者的临床及生物学特征。 结果: 23例非IgM型LPL患者中,2例分泌单克隆性IgA,14例分泌单克隆性IgG,7例不分泌单克隆性免疫球蛋白。非IgM型LPL和WM患者中位年龄均为62(35~81)岁。与WM组患者相比,非IgM型LPL组患者女性(56.5%对27.3%,P=0.007)、脾大(60.1%对43.8%,P=0.100)、结外侵犯(21.7%对12.3%,P=0.672)比例更高。非IgM型LPL组18例患者进行了MYD88基因相关检测,阳性率55.6%。非IgM型LPL组17例患者接受了治疗,启动治疗的患者比例与WM组患者相当(94.4%对92.7%,P=0.488)。非IgM型LPL组16例患者进行了疗效评价,一线治疗总体缓解率87.5%,中位随访时间33.9(3.5~125.1)个月,总体中位无进展生存(PFS)、总生存(OS)时间未达到,3年PFS率和OS率分别为71.4%和68.9%。WM组中位PFS、OS时间分别为66.2个月和78.1个月。两组PFS、OS的差异均无统计学意义(P值分别为0.340、0.544)。 结论: 非IgM型LPL与WM患者的临床及生物学特征相似,但非IgM型LPL组女性、结外受累比例更高。非IgM型LPL患者的生存及预后与WM患者相似。.
引用
- Yu Y, Xiong WJ, Chen JW, et al. [Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709134. doi:10.3760/cma.j.issn.0253-2727.2022.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。